Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
View ORCID ProfileNatalia Vargas-Herrera, View ORCID ProfileManuel Fernández-Navarro, Nestor E Cabezudo, Percy Soto-Becerra, View ORCID ProfileGilmer Solís-Sánchez, View ORCID ProfileStefan Escobar-Agreda, Javier Silva-Valencia, Luis Pampa-Espinoza, View ORCID ProfileRicardo Bado-Pérez, Lely Solari, View ORCID ProfileRoger V Araujo-Castillo
doi: https://doi.org/10.1101/2022.05.01.22274548
Natalia Vargas-Herrera
1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Manuel Fernández-Navarro
1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Nestor E Cabezudo
2Measles and Rubella National Reference Laboratory, Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Percy Soto-Becerra
3Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI), Seguro Social de Salud del Peru (ESSALUD), Lima, Peru
Gilmer Solís-Sánchez
4Oficina General de Investigación y Transferencia Tecnológica, Instituto Nacional de Salud, Lima, Peru
Stefan Escobar-Agreda
1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Javier Silva-Valencia
1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Luis Pampa-Espinoza
1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Ricardo Bado-Pérez
5Centro Nacional de Epidemiología, Prevención y Control de Enfermedades, Ministerio de Salud – Perú, Lima, Peru
Lely Solari
1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Roger V Araujo-Castillo
1Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Peru
Article usage
Posted May 03, 2022.
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
Natalia Vargas-Herrera, Manuel Fernández-Navarro, Nestor E Cabezudo, Percy Soto-Becerra, Gilmer Solís-Sánchez, Stefan Escobar-Agreda, Javier Silva-Valencia, Luis Pampa-Espinoza, Ricardo Bado-Pérez, Lely Solari, Roger V Araujo-Castillo
medRxiv 2022.05.01.22274548; doi: https://doi.org/10.1101/2022.05.01.22274548
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
Natalia Vargas-Herrera, Manuel Fernández-Navarro, Nestor E Cabezudo, Percy Soto-Becerra, Gilmer Solís-Sánchez, Stefan Escobar-Agreda, Javier Silva-Valencia, Luis Pampa-Espinoza, Ricardo Bado-Pérez, Lely Solari, Roger V Araujo-Castillo
medRxiv 2022.05.01.22274548; doi: https://doi.org/10.1101/2022.05.01.22274548
Subject Area
Subject Areas
- Addiction Medicine (353)
- Allergy and Immunology (675)
- Anesthesia (181)
- Cardiovascular Medicine (2672)
- Dermatology (226)
- Emergency Medicine (404)
- Epidemiology (12290)
- Forensic Medicine (10)
- Gastroenterology (768)
- Genetic and Genomic Medicine (4143)
- Geriatric Medicine (388)
- Health Economics (682)
- Health Informatics (2684)
- Health Policy (1008)
- Hematology (365)
- HIV/AIDS (857)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (443)
- Neurology (3924)
- Nursing (212)
- Nutrition (584)
- Oncology (2063)
- Ophthalmology (592)
- Orthopedics (243)
- Otolaryngology (306)
- Pain Medicine (251)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1125)
- Primary Care Research (459)
- Public and Global Health (6562)
- Radiology and Imaging (1413)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (344)
- Surgery (454)
- Toxicology (54)
- Transplantation (189)
- Urology (169)